These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 14534738)

  • 1. Aphidicolin decreases ex vivo resistance to cytosine arabinoside in childhood acute leukaemia.
    Sargent JM; Williamson CJ; Hubeek I; Elgie AW; Taylor CG; Den Boer ML; Peters GJ; Kaspers GL
    Oncol Rep; 2003; 10(6):2027-31. PubMed ID: 14534738
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circumvention of ara-C resistance by aphidicolin in blast cells from patients with AML.
    Sargent JM; Elgie AW; Williamson CJ; Lewandowicz GM; Taylor CG
    Br J Cancer; 2001 Mar; 84(5):680-5. PubMed ID: 11237390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aphidicolin markedly increases the in vitro sensitivity to ara-C of blast cells from patients with AML.
    Sargent JM; Elgie AW; Williamson CJ; Taylor CG
    Adv Exp Med Biol; 1999; 457():567-70. PubMed ID: 10500835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potentiation of in vitro ara-C cytotoxicity by ribonucleotide reductase inhibitors, cyclin-dependent kinase modulators and the DNA repair inhibitor aphidicolin in paediatric acute myeloid leukaemia.
    Hubeek I; Peters GJ; Broekhuizen AJ; Sargent J; Gibson BE; Creutzig U; Kaspers GJ
    Br J Haematol; 2005 Oct; 131(2):219-22. PubMed ID: 16197453
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intracellular retention of cytosine arabinoside triphosphate in blast cells from children with acute myelogenous and lymphoblastic leukemia.
    Boos J; Hohenlöchter B; Schulze-Westhoff P; Schiller M; Zimmermann M; Creutzig U; Ritter J; Jurgens H
    Med Pediatr Oncol; 1996 Jun; 26(6):397-404. PubMed ID: 8614376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of multidrug resistance (MDR) proteins and in vitro drug resistance in acute leukemias.
    Fazlina N; Maha A; Jamal R; Zarina AL; Cheong SK; Hamidah H; Ainoon O; Zulkifli SZ; Hamidah NH
    Hematology; 2007 Feb; 12(1):33-7. PubMed ID: 17364990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters].
    Schiller M; Hohenlöchter B; Schulze-Westhoff P; Zimmermann M; Ritter J; Jürgens H; Boos J
    Klin Padiatr; 1996; 208(4):151-9. PubMed ID: 8926681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of DNA ligase I by 1-beta-D-arabinosylcytosine and aphidicolin in MiaPaCa human pancreatic cancer cells.
    Sun D; Urrabaz R; Buzello C; Nguyen M
    Exp Cell Res; 2002 Oct; 280(1):90-6. PubMed ID: 12372342
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ex vivo drug resistance profile in childhood acute myelogenous leukemia: no drug is more effective in comparison to acute lymphoblastic leukemia.
    Styczynski J; Wysocki M; Debski R; Juraszewska E; Malinowska I; Stanczak E; Ploszynska A; Stefaniak J; Mazur B; Szczepanski T
    Leuk Lymphoma; 2002 Sep; 43(9):1843-8. PubMed ID: 12685842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydrocortisone in culture protects the blast cells in acute myeloblastic leukemia from the lethal effects of cytosine arabinoside.
    Yang GS; Wang C; Minkin S; Minden MD; McCulloch EA
    J Cell Physiol; 1991 Jul; 148(1):60-7. PubMed ID: 1860896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome.
    Zwaan CM; Kaspers GJ; Pieters R; Hählen K; Janka-Schaub GE; van Zantwijk CH; Huismans DR; de Vries E; Rots MG; Peters GJ; Jansen G; Creutzig U; Veerman AJ
    Blood; 2002 Jan; 99(1):245-51. PubMed ID: 11756178
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and pharmacodynamic studies of fludarabine and cytosine arabinoside administered as loading boluses followed by continuous infusions after a phase I/II study in pediatric patients with relapsed leukemias. The Children's Cancer Group.
    Avramis VI; Wiersma S; Krailo MD; Ramilo-Torno LV; Sharpe A; Liu-Mares W; Kowck R; Reaman GH; Sato JK
    Clin Cancer Res; 1998 Jan; 4(1):45-52. PubMed ID: 9516951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Consolidation therapy for childhood acute lymphoblastic leukaemia: clinical and cellular pharmacology of cytosine arabinoside, epipodophyllotoxins and cyclophosphamide.
    Estlin EJ; Yule SM; Lowis SP
    Cancer Treat Rev; 2001 Dec; 27(6):339-50. PubMed ID: 11908927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regulation by retinoic acid and hydrocortisone of the anthracycline sensitivity of blast cells of acute myeloblastic leukemia.
    Yang GS; Minden MD; McCulloch EA
    Leukemia; 1994 Dec; 8(12):2065-75. PubMed ID: 7807996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relation of blast cell survival and proliferation to chemotherapy resistance in AML.
    Nørgaard JM; Langkjer ST; Palshof T; Clausen N; Pedersen B; Hokland P
    Br J Haematol; 1996 Jun; 93(4):888-97. PubMed ID: 8703822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ex vivo activity of thalidomide in childhood acute leukemia.
    Styczynski J; Czyzewski K; Wysocki M
    Leuk Lymphoma; 2006 Jun; 47(6):1123-8. PubMed ID: 16840205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
    Avramis IA; Laug WE; Sausville EA; Avramis VI
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytosine arabinoside (ara-C) and cis-dichlorodiammineplatinum II (cisplatin) alone and in combination: effects on acute myeloblastic leukemia blast cells in culture and in vivo.
    Wang YF; Curtis JE; Lipton J; Minkin S; McCulloch EA
    Leukemia; 1991 Jun; 5(6):522-7. PubMed ID: 1711641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disulfiram overcomes bortezomib and cytarabine resistance in Down-syndrome-associated acute myeloid leukemia cells.
    Bista R; Lee DW; Pepper OB; Azorsa DO; Arceci RJ; Aleem E
    J Exp Clin Cancer Res; 2017 Feb; 36(1):22. PubMed ID: 28143565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The sensitivity to cytosine arabinoside of the blast progenitors of acute myeloblastic leukemia.
    Nara N; Curtis JE; Senn JS; Tritchler DL; McCulloch EA
    Blood; 1986 Mar; 67(3):762-9. PubMed ID: 3456247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.